Structure Therapeutics (NASDAQ:GPCR) Shares Up 12.2% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) shares rose 12.2% during trading on Tuesday . The company traded as high as $74.10 and last traded at $77.8370. Approximately 314,377 shares were traded during trading, a decline of 65% from the average daily volume of 900,331 shares. The stock had previously closed at $69.36.

Analysts Set New Price Targets

GPCR has been the topic of several recent research reports. Citizens Jmp boosted their price objective on shares of Structure Therapeutics from $87.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Friday, December 12th. HC Wainwright increased their price target on shares of Structure Therapeutics from $60.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Jefferies Financial Group set a $125.00 price objective on Structure Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 11th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Finally, Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $99.11.

Structure Therapeutics Price Performance

The stock has a market cap of $4.79 billion, a price-to-earnings ratio of -64.72 and a beta of -2.05. The firm’s 50-day moving average is $51.24 and its 200 day moving average is $32.46.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors have recently modified their holdings of the company. State of Wyoming purchased a new position in Structure Therapeutics in the second quarter valued at approximately $28,000. EverSource Wealth Advisors LLC raised its stake in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after acquiring an additional 901 shares during the period. Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after acquiring an additional 994 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.